TrialNature communications2026

The efficacy, immunogenicity and safety of the LZ901 vaccine for herpes zoster virus in adults 40 years of age or older: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Pengfei Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.